Table 1 Characteristics of meningioma discovery cohort and external testing cohort 1
|  | Integrated cohort, N = 565a | Discovery, N = 200a | External Testing 1, N = 365a |
|---|---|---|---|
Follow-up (years) | 5.6 (2.0–9.6) | 6.3 (2.5–11.3) | 5.3 (1.9–8.5) |
Local recurrence at follow-up | 161 (28.5) | 73 (36.5) | 88 (24.1) |
Local freedom from recurrence, years | 3.8 (1.2–8.0) | 11.8 (7.3—not reached) | Not reached |
Deceased at follow-up | 137 (24.2) | 59 (29.5) | 78 (21.4) |
Sex | |||
 F | 374 (66.2) | 127 (63.5) | 247 (67.7) |
 M | 191 (33.8) | 73 (36.5) | 118 (32.3) |
Age at surgery | 58 (47–67) | 57 (45–66) | 58 (48–68) |
Extent of resection | |||
 Gross total | 394 (70.7) | 118 (59.0) | 276 (77.3) |
 Subtotal | 158 (28.4) | 77 (38.5) | 81 (22.7) |
 Biopsy | 5 (0.9) | 5 (2.5) | 0 (0.0) |
 Unknown | 8 | 0 | 8 |
Recurrent | 109 (19.3) | 43 (21.5) | 66 (18.1) |
WHO 2016 grade | |||
 1 | 388 (68.7) | 87 (43.5) | 301 (82.5) |
 2 | 142 (25.1) | 83 (41.5) | 59 (16.2) |
 3 | 35 (6.2) | 30 (15.0) | 5 (1.4) |
Adjuvant radiotherapy | 89 (15.8) | 45 (22.5) | 44 (12.1) |
CDKN2A/B loss | 37 (6.5) | 22 (11.0) | 15 (4.1) |
Mitoses per 10 HPF | 0.00 (0.00–1.00) | 0.00 (0.00–2.00) | 0.00 (0.00–1.00) |
DNA methylation group | |||
 Immune-enriched | 216 (38.2) | 65 (32.5) | 151 (41.4) |
 Merlin-intact | 192 (34.0) | 72 (36.0) | 120 (32.9) |
 Hypermitotic | 157 (27.8) | 63 (31.5) | 94 (25.8) |
